(Circulation. 2000;102:2758.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Synthesis Depresses Contractility of Isolated Rat Hearts
From the Department of Internal Medicine (U.G., L.F., A.B., M.H., H.-J.K., K.M., W.S., F.G., U.S.) and the Department of Pathology (L.F., R.M.B.), Justus-Liebig-University, Giessen, Germany; and the Second Department of Internal Medicine (M.B.), Johannes-Gutenberg-University, Mainz, Germany.
Correspondence to Ulf Sibelius, MD, Department of Internal Medicine, Klinikstrasse 36, D-35392 Giessen, Germany. E-mail ulf.sibelius{at}innere.med.uni-giessen.de
| Abstract |
|---|
|
|
|---|
Methods and ResultsPerfusion of isolated rat hearts with LPS for
180 minutes resulted in a decline of left ventricular
contractility after 90 minutes, whereas
coronary perfusion pressure remained unaffected. This
cardiodepression was paralleled by a release of tumor necrosis
factor (TNF)-
into the perfusate and preceded by myocardial
TNF-
mRNA upregulation as quantified by real-time polymerase chain
reaction. The cardiodepression was abrogated when LPS was perfused with
a TNF-
antiserum or the ceramidase inhibitor
N-oleoylethanolamine. In contrast, the cardiac release
of nitric oxide (NO) was not augmented by LPS. Immunohistochemical
studies of LPS-perfused hearts revealed a positive staining for the
constitutive (NOSIII) but not for the inducible NO synthase (NOSII).
Accordingly, NOSII mRNA levels commenced to increase only at the very
end of the LPS perfusion period. Progressive liberation of
thromboxane (Tx) A2 and prostacyclin was
induced by LPS together with myocardial
cyclooxygenase (Cox)-2 mRNA expression. Both
nonselective inhibition of Cox by indomethacin and
selective inhibition of the inducible Cox-2 by NS-398 abolished
prostanoid release. Interestingly, the generation of TNF-
and the
associated cardiodepression caused by LPS were reduced by
indomethacin, NS-398 and the Tx-receptor
antagonist daltroban.
ConclusionsLPS depresses contractility of
isolated rat hearts by inducing TNF-
synthesis and subsequently
activating the sphingomyelinase pathway, whereas no evidence for a role
of NOSII- or NOSIII-generated NO was found. Moreover, Cox-2derived
TxA2 appears to facilitate TNF-
synthesis in response to
LPS.
Key Words: contractility nitric oxide nitric oxide synthase perfusion heart failure shock
| Introduction |
|---|
|
|
|---|
Cardiodepressant properties of serum from septic patients have
largely been attributed to cytokines, in particular tumor
necrosis factor (TNF)-
and interleukin-1ß.5 6 TNF-
impairs contractile performance in intact animals, isolated
hearts, and cardiomyocytes.7 8 9 10 11 Within
minutes, TNF-
reduces myocardial contractility in
vitro by disturbing intracellular Ca2+
homeostasis,10 and activation of the sphingomyelinase
pathway has been suggested as underlying mechanism.8 11
Sphingomyelinases yield ceramide from membrane-bound sphingomyelin,
which may be converted by ceramidase into sphingosine. This agent was
shown to inhibit the release of intracellular
Ca2+ through the sarcoplasmatic reticular
ryanodine receptor12 and to depress the L-type calcium
current.13 As a different concept, negative inotropic
effects of TNF-
were attributed to enhanced synthesis of nitric
oxide (NO) in the myocardium via the constitutively
expressed NOSIII6 14 or the inducible isoform
(NOSII).9 15 Recent studies demonstrated that the
myocardial tissue itself synthesizes TNF-
in response to various
challenges, including LPS exposure.16 17 18
Apart from circulating cytokines, sepsis-associated impairment
of regional perfusion may extend to the coronary vasculature,
and maldistribution of myocardial perfusion with disturbances
in regional O2 supply may depress myocardial
performance.19 20 21 22 23 Vasoactive prostanoids
synthesized by the constitutively expressed
cyclooxygenase (Cox)-1 and under septic conditions
increasingly by the inducible Cox-2 may contribute to the perfusion
maldistribution of sepsis. Recently, significant expression of Cox-2
has been demonstrated in septic human and endotoxic rat
heart,24 25 and in a very recent study from our laboratory
we showed that the myocardial depression of isolated rat hearts in
response to staphylococcal
-toxin results from
thromboxane (Tx)A2 liberation with
coronary vasoconstriction and perfusion
mismatch.23
The purpose of this study was to investigate whether endotoxin
depresses contractility of isolated buffer-perfused rat
hearts and, if so, to study the mechanisms involved. We noted an
LPS-induced cardiodepression associated with myocardial upregulation of
TNF-
and subsequent activation of the sphingomyelinase pathway. In
contrast, cardiac NO generation did not contribute to the negative
inotropism of LPS. Moreover, Cox-2derived TxA2
is suggested to act as a paracrine facilitator of TNF-
synthesis,
thereby contributing to LPS-evoked cardiac dysfunction.
| Methods |
|---|
|
|
|---|
antiserum, cross-reacting with rat TNF-
,26 was
purchased from Genzyme Virotech, the ceramidase inhibitor
N-oleoylethanolamine (NOE) from Sigma,
indomethacin from ICN Biomedicals, the selective Cox-2
inhibitor NS-39827 from Calbiochem, and
the TxA2 receptor antagonist
daltroban (BM 13.505) from Boehringer. Other materials used are
stated below.
Isolated Heart Perfusion and Experimental Protocols
Materials and techniques of preparation, perfusion, and
monitoring of physiological parameters
have been described by us in detail.23 All hearts were
perfused in a recirculating mode (total volume, 50 mL). LPS, 0.1 or 1.0
µg/mL, were perfused for 180 minutes. Perfusate samples for
determination of TNF-
, TxB2, 6-keto
prostaglandin (PG)F1
, lactate
dehydrogenase (LDH), and creatine kinase (CK) were taken twice before
and 30, 60, 90, 120, 150, and 180 minutes after LPS application. For
pharmacological intervention, either TNF-
antiserum (0.4% vol/vol),
NOE (5 µmol/L), indomethacin (100
µmol/L), NS-398 (25 µmol/L), or daltroban (10 µmol/L)
was admixed to the perfusate before LPS application (1 µg/mL)
Control experiments included perfusion solely with perfusate
and with perfusate enriched with the respective pharmacological
inhibitors.
Measurement of TNF-
, TxA2, Prostacyclin, CK,
and LDH
TNF-
was measured with a rat TNF-
ELISA (Biosource).
TxA2 and prostacyclin were quantified by
measuring their stable hydrolysis products
TxB2 and 6-keto PGF1
by
ELISA (Cayman Chemical Co). LDH and CK were measured by routine
techniques.
Measurement of NO
NO was detected as described by us previously.28 NO
is rapidly converted to nitrite and nitrate, summarized as
NOx, in the oxygen-containing perfusate.
To monitor NOx perfusate, samples were
transferred to a reaction vessel containing 80 mL of 0.1 mol/L vanadium
(III) chloride in 2.0 mol/L HCL at 98°C. This solution quantitatively
reduced NOx to NO. NO was removed from the
reaction vessel by oxygen-free nitrogen continuously flushing through
the liquid (160 mL/min), which entered a chemiluminescence detector
(UPK300; UPK). Calibration was performed with known amounts of nitrite
and nitrate.
Immunohistochemical Analysis of NOSII/NOSIII Expression
in Myocardium
Specimens of the left ventricle were prepared for
immunohistochemical analysis as plastic sections, as described
by us previously.23 Immunohistochemical procedures were
performed as described by Beckstead et al,29 with the
avidin-biotin immunoperoxidase technique (Vectastain ABC Reagent,
Vector Laboratories). Immunohistochemical analysis was
performed with antibodies against NOSIII and NOSII (Stressgene).
Incubation of the primary antibodies was carried out overnight at
different dilutions, of which 1:50 gave the highest degree of
immunolocalization and the least nonspecific background staining. The
sections were lightly counterstained with Gills hematoxylin 3 (Sigma)
and examined with a Zeiss light microscope at x400.
Quantitative Analysis of mRNA
To determine mRNA expression, hearts were perfused for various
time periods with or without LPS.
mRNA Extraction
Cryosections of the left ventricle were lysed in 300 µL lysis
buffer of the Dynabeads mRNA direct
kit (Dynal). mRNA was caught by attachment to oligo-dT fragments
coupled to supermagnetic glass particles. Per sample, 100-µg beads
were applied. mRNA was finally dissolved in 20 µL DEPC-treated
H2O.
mRNA Quantification
This was performed by the Sequence Detection System 7700 (PE
Applied Biosystems) and real-time polymerase chain reaction (PCR), with
comparative quantification (
CT) and normalizing the target gene to
an internal standard gene according to the formula
![]() |
For internal calibration, porphobilinogen deaminase (PBGD) mRNA was
used, a ubiquitously and consistently expressed standard gene
without pseudogenes.30 In preliminary experiments,
amplification efficiency of PBGD, TNF-
, NOSII, NOSIII, and Cox-2
primer/probe sets was approximately equal and amounted to 0.9±0.02
(90±2%).
cDNA Synthesis and Real-Time PCR
cDNA synthesis and real-time PCR were performed as described
previously by us.31 Two µL cDNA was applied to each
sample. Oligonucleotide primers
(Table
) were added to a final
concentration of 300 nmol/L each and hybridization probes
(Table
) to a final concentration of 200
nmol/L in a volume of 50 µL. Cycling conditions were adapted to
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds,
61°C for 60 seconds.
|
Statistical Analysis
All data are given as mean±SEM and were analyzed by
1-way ANOVA followed by Tukeys honestly significant difference test.
A value of P<0.05 was considered to be significant.
| Results |
|---|
|
|
|---|
90 minutes, which further progressed until terminating the
experiments. In contrast, no significant change in coronary
perfusion pressure (CPP) was observed (Figure 1C
|
Perfusion of LPS Results in Liberation of TNF-
, Which
Is Preceded by Myocardial Expression of TNF-
mRNA
In the recirculating perfusate of control hearts, only
trace amounts of TNF-
accumulated over 180 minutes. In contrast, a
dose-dependent rise in TNF-
levels occurred in the presence of LPS,
commencing after 90 minutes and progressing until the end of the
experiments (Figure 2A
).
|
Quantification of TNF-
mRNA showed a significant expression after 60
minutes exposure to endotoxin, thus preceding the liberation of
TNF-
in the perfusate (Figure 2B
). This expression
increased considerably for the remainder of perfusion time. In
contrast, no TNF-
mRNA expression was observed in time-matched
controls except for a minimal expression after 180 minutes.
In the Presence of LPS, Release of NO Is Not Augmented and NOSII
mRNA Is Elevated Only After 180 Minutes
NOx accumulation in the perfusate of
control hearts, signaling ongoing NO liberation, was not enhanced by
LPS (Figure 3A
). Moreover, no NOSII mRNA
expression was found in control and LPS-challenged hearts, except for
LPS-perfused hearts after 180 minutes (Figure 3B
).
Immunohistochemical analysis of LPS-treated hearts showed a
positive staining for NOSIII in the coronary
endothelium (Figure 4
)
but no significant staining for NOSII (not shown) after 180 minutes.
Likewise, only positive staining for NOSIII but not NOSII was noted in
time-matched control hearts (not shown), and NOSIII mRNA expression in
LPS-challenged (1.0 µg/mL) hearts did not differ significantly from
controls after 0, 60, 120, and 180 minutes (not shown).
|
|
LPS Provokes Release of TxA2 and Prostacyclin and
Augmentation of Cox-2 mRNA
Only minor quantities of TxB2, the stable
metabolite of TxA2, accumulated in the
perfusate of control hearts within 180 minutes.
TxA2 liberation was dose-dependently augmented by
LPS after 60 minutes (Figure 5
).
Similarly, the basal release of 6-keto PGF1
(343±50 pg/mL at 0 minutes, 3748±526 pg/mL at 180 minutes in control
hearts) was markedly increased in the presence of 0.1 µg/mL LPS
(485±73 pg/mL at 0 minutes, 8077±2131 pg/mL at 180 minutes) and 1.0
µg/mL LPS (205±64 pg/mL at 0 minutes, 12 258±1973 pg/mL at 180
minutes). At the end of the perfusion period, Cox-2 mRNA was augmented
9-fold (14.70±6.83 copies Cox-2 mRNA/1 copy PBGD mRNA) compared
with control hearts (1.65±0.60 copies Cox-2 mRNA/1 copy PBGD
mRNA).
|
Inhibitory Capacities of Anti-TNF-
, NOE,
Indomethacin, NS-398, and Daltroban
TNF-
antiserum completely abolished the cardiodepression
by LPS (Figure 6
, A and B). Similarly,
the LPS-induced cardiodepression was completely abrogated in the
presence of the ceramidase inhibitor NOE.
Indomethacin, the selective Cox-2 inhibitor
NS-398, and the specific thromboxane-receptor
antagonist daltroban partially prevented the LPS-induced
cardiodepression. Indomethacin blocked cardiac
TxB2 (Figure 5
) and 6-keto
PGF1
release (374±132 pg/mL at 0 minutes,
550±154 pg/mL at 180 minutes) to very low levels, and when LPS was
perfused in the presence of NS-398, TxB2 and
6-keto PGF1
levels were also dramatically
reduced (6-keto PGF1
, 1018±518 pg/mL after
180 minutes; Figure 5
). As anticipated, the cardiac prostanoid
generation was not affected by daltroban (not shown). CPP was not
significantly affected by any compound (Figure 6C
). In separate
control experiments, none of the drugs/antiserum used were found to
alter CPP, LVDP, and dP/dtmax in the absence of
LPS (data not shown).
|
Indomethacin, NS-398, and Daltroban Partly Inhibit
LPS-Induced TNF-
Liberation
In the presence of indomethacin, the LPS-evoked
TNF-
release was reduced by nearly 50% (Figure 7
). Nearly identical inhibition was noted
for the selective Cox-2 inhibitor NS-398 and the
thromboxane receptor antagonist daltroban.
|
LPS Does Not Affect Endothelial Permeability and
Release of CK and LDH
The weight gain of hearts undergoing 180 minutes of LPS (1.0
µg/mL) perfusion was 338±22 mg (baseline weight, 1018±66 mg), which
did not significantly differ from 294±27 mg in buffer-perfused control
hearts (baseline heart weight, 914±57 mg). CK and LDH
perfusate levels did not differ significantly between control
and LPS-perfused (1.0 µg/mL) hearts.
| Discussion |
|---|
|
|
|---|
synthesis with subsequent activation of the
sphingomyelinase pathway is a major effector of myocardial depression.
In contrast, no evidence for a contribution of NO to the early negative
inotropic effect of LPS was obtained in this model. Endotoxin-elicited
Cox-2-derived thromboxane generation is proposed as an
autocrine facilitator of LPS-induced TNF-
generation.
The cardiodepression became obvious within
90 minutes of LPS
perfusion and progressed steadily until the end of the experiments,
whereas CPP remained unaffected. This may be surprising, as endotoxin
provoked a marked liberation of the vasoconstrictor
thromboxane into the coronary bed. The most
reasonable explanation for this observation is the finding that
thromboxane release was accompanied by prominent
prostacyclin liberation, and this vasodilatory agent might antagonize
the vasomotor effects of TxA2. Thus, perfusion
abnormalities are very unlikely to contribute to the negative inotropic
effect of LPS in the buffer-perfused hearts.
In contrast, cardiac synthesis of TNF-
in response to LPS, preceded
by myocardial expression of TNF-
mRNA, offers the most plausible
explanation for the loss of contractility. TNF-
release into the coronary vasculature and negative inotropism
progressed in a nearly superimposable fashion. Comparable dose
dependence was noted for both events, and the myocardial depression was
completely abrogated in the presence of a TNF-
antiserum. From our
studies, we cannot deduce the origin of cardiac TNF-
synthesis.
However, recent investigations have convincingly demonstrated that
endothelial and smooth muscle cells of the
coronary vasculature and particularly
cardiomyocytes themselves are capable of synthesizing this
cytokine.16 17 18
Cardiodepressive effects of TNF-
have been ascribed to at least 2
different mechanisms. The immediate cardiodepression by TNF-
might
either be mediated by activation of the sphingomyelinase
pathway8 11 or by activation of the constitutive
NOSIII,6 14 whereas a more delayed cardiodepression of
TNF-
might be attributed to "extra" NOSII-derived NO
release.9 15 Monitoring of NO-release demonstrated ongoing
accumulation of NOx32; however,
kinetics were indistinguishable in control and LPS hearts, thus
excluding any major impact of LPS per se or LPS-evoked TNF-
on
baseline NO formation. Moreover, immunohistochemical studies showed a
strong positive staining for NOSIII, distributed in the vascular
endothelium of myocardial vessels, but no significant
staining for NOSII in control or LPS-perfused hearts. Accordingly,
NOSII mRNA expression increased only at the very end of the perfusion
period. Because the expression of NOSII is regulated at transcriptional
levels and demands a few hours lag phase,9 15 the NOSII
mRMA induction at the end of our experimental protocol might indicate
the onset of "excessive" NO synthesis, which might then contribute
to a more delayed LPS-mediated cardiodepression occurring beyond the
time range studied here. However, under the current experimental
conditions, a major role of NOSII- or NOSIII-mediated NO formation in
the LPS-induced cardiodepression is largely excluded.
In contrast, the cardiodepression in LPS-perfused hearts was completely
abolished in the presence of the specific ceramidase
inhibitor NOE. This finding suggests a sequence of
TNF-
induced activation of the sphingomyelinase pathway with
formation of sphingosine as the underlying mechanism. It is well in
line with this suggestion that sphingosine is known to be produced in
TNF-
exposed cardiomyocytes within minutes, together
with a loss of contractility,11 and that
superfusion of cardiomyocytes with the effluent of
LPS-challenged hearts containing TNF-
provokes corresponding
effects.16 Additional evidence for a role of sphingosine
in TNF-
induced myocardial depression was recently obtained from
isolated rat hearts directly perfused with this
cytokine.8
Another remarkable finding of the present study is the fact that
inhibition of cyclooxygenase activity by
indomethacin or the selective Cox-2
inhibitor NS-39827 inhibited the release of
TxA2. Together with the fact that Cox-2 mRNA was
upregulated in the myocardium of LPS-perfused hearts, this
finding supports the notion that LPS-induced TxA2
liberation proceeds largely through upregulation of Cox-2.
Interestingly, inhibition of Cox activity by a nonselective Cox
inhibitor and the selective Cox-2 inhibitor as
well as administration of a specific thromboxane receptor
antagonist reduced TNF-
formation and the
cardiodepression in response to LPS. This observation is reminiscent of
the recent finding in human monocytes that blocking
TxA2 decreased zymosan-induced TNF-
production, which was partly reproduced by a stable Tx receptor
agonist.33 Supporting this notion, suppression of
TNF-
synthesis by a TxA2 inhibitor
was also observed in liver ischemia34 and
alcoholic liver disease35 in the rat. Taken together,
these data suggest that TxA2, largely originating
from upregulated Cox-2, may act as a paracrine facilitator of TNF-
synthesis.
In summary, the present study provides evidence that TNF-
is
both generated and biologically active in the myocardium of
endotoxin-exposed rat hearts. The LPS-induced early loss in contractile
force is suggested to proceed largely through TNF-
elicited
sphingosine formation and not through impact on cardiac NO synthesis.
Interestingly, Cox-2derived TxA2 may act as a
paracrine facilitator of LPS-induced TNF-
liberation.
| Acknowledgments |
|---|
Received March 27, 2000; revision received June 26, 2000; accepted June 26, 2000.
| References |
|---|
|
|
|---|
2. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483490.
3. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280287.[Abstract]
4.
Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin
and tumor necrosis factor challenges in dogs stimulate the
cardiovascular profile of human septic shock. J
Exp Med.. 1989;169:823832.
5.
Kumar A, Thota V, Dee L, et al. Tumor necrosis
factor
and interleukin 1ß are responsible for in vitro
myocardial depression induced by human septic shock serum. J Exp
Med. 1996;183:949958.
6.
Kumar A, Brar R, Wang P, et al. Role of nitric oxide
and cGMP in human septic serum-induced depression of cardiac myocyte
contractility. Am J Physiol. 1999;276:R265R276.
7.
Bozkurt B, Kribbs SB, Clubb FJ, et al.
Pathophysiologically relevant concentrations of
tumor necrosis factor-
promote progressive left
ventricular dysfunction and remodeling in rats.
Circulation. 1998;97:13821391.
8.
Edmunds NJ, Lal H, Woodward B. Effects of tumour
necrosis factor-
on left ventricular function in
the rat isolated perfused heart: possible mechanisms for a decline in
cardiac function. Br J Pharmacol. 1999;126:189196.[Medline]
[Order article via Infotrieve]
9. Stein B, Frank P, Schmitz W, et al. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol. 1996;28:16311639.[Medline] [Order article via Infotrieve]
10.
Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis
for the negative inotropic effects of tumor necrosis factor-
in
the adult mammalian heart. J Clin Invest. 1993;92:23032312.
11.
Oral H, Dorn GW II, Mann DL. Sphingosine mediates the
immediate negative inotropic effects of tumor necrosis factor-
in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:48364842.
12. Dettbarn CA, Betto R, Salviata G, et al. Modulation of cardiac sarcoplasmatic reticulum ryanodine receptor by sphingosine. J Mol Cell Cardiol. 1994;26:229242.[Medline] [Order article via Infotrieve]
13.
McDonough PM, Yasui K, Betto R, et al. Control of
cardiac Ca2+ levels: inhibitory
actions of sphingosine on Ca2+ transients and
L-type Ca2+ channel conductance. Circ
Res. 1994;75:981989.
14.
Finkel MS, Oddis CV, Jacob TD, et al. Negative
inotropic effects of cytokines on the heart mediated by nitric
oxide. Science. 1992;257:387389.
15. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575580.[Medline] [Order article via Infotrieve]
16.
Kapadia S, Lee J, Torre-Amione G, et al. Tumor necrosis
factor-
gene and protein expression in adult feline
myocardium after endotoxin administration. J
Clin Invest. 1995;96:10421052.
17.
Gurevitch J, Frolkis I, Yuhas Y, et al. Anti-tumor
necrosis factor-
improves myocardial recovery after
ischemia and reperfusion. J Am Coll Cardiol. 1997;30:15541561.[Abstract]
18.
Meldrum DR, Cleveland JC, Cain BS, et al. Increased
myocardial tumor necrosis factor-
in a crystalloid-perfused
model of cardiac ischemia-reperfusion injury. Ann Thorac
Surg. 1998;65:439443.
19. Hersch M, Gnidec AA, Bersten AD, et al. Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery. 1990;107:397410.[Medline] [Order article via Infotrieve]
20.
Groenevald ABJ, van Lambalgen AA, van den Bos GC, et
al. Maldistribution of heterogeneous coronary blood
flow during canine endotoxin shock. Cardiovasc Res. 1991;25:8088.
21. Fox GA, Bersten A, Lam C, et al. Hematocrit modifies the circulatory control of systemic and myocardial oxygen utilization in septic sheep. Crit Care Med. 1994;22:470479.[Medline] [Order article via Infotrieve]
22. Bloos FM, Morisaki HM, Neal AM, et al. Sepsis depresses the metabolic oxygen reserve of the coronary circulation in mature sheep. Am J Respir Crit Care Med. 1996;153:15771584.[Abstract]
23.
Sibelius U, Grandel U, Buerke M, et al.
Staphylococcal
-toxin provokes coronary
vasoconstriction and loss in myocardial contractility
in perfused rat hearts: role of thromboxane formation.
Circulation. 2000;101:7885.
24.
Wong SCY, Fukuchi M, Melnyk P, et al. Induction of
cyclooxygenase-2 and activation of nuclear
factor-
B in myocardium of patients with congestive
heart failure. Circulation. 1998;98:100103.
25. Liu SF, Newton R, Evans TW, et al. Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci. 1996;90:301306.[Medline] [Order article via Infotrieve]
26. Martin A, Molina A, Bricio T, et al. Passive dual immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta maximally ameliorates acute aminonucleoside nephrosis. Clin Exp Immunol. 1995;99:283288.[Medline] [Order article via Infotrieve]
27. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47:5559.[Medline] [Order article via Infotrieve]
28.
Schütte H, Mayer K, Gessler T, et al. Nitric
oxide biosynthesis in an exotoxin-induced septic lung model: role of
cNOS and impact on pulmonary hemodynamics.
Am J Respir Crit Care Med. 1998;157:498504.
29.
Beckstead JH, Stenberg PE, McEver RP, et al.
Immunohistochemical localization of membrane and alpha-granule proteins
in human megakaryocytes: application to plastic embedded bone marrow
biopsy specimens. Blood. 1986;67:285293.
30. Fink L, Stahl U, Ermert L, et al. Rat porphobilinogen deaminase gene: a pseudogene-free internal standard for laser-assisted cell picking. Biotechniques. 1999;26:510516.[Medline] [Order article via Infotrieve]
31. Fink L, Seeger W, Ermert L, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 1998;11:13291333.
32.
Kelm M, Schrader J. Control of coronary
vascular tone by nitric oxide. Circ Res. 1990;66:15611575.
33.
Caughey GE, Pouliot M, Cleland LG, et al. Regulation of
tumor necrosis factor-
and IL- 1ß synthesis by
thromboxane A2 in nonadherent human
monocytes. J Immunol. 1997;158:351358.[Abstract]
34. Sugawawa Y, Harihara Y, Yakayama T, et al. Suppression of cytokine production by thromboxane A2 inhibitor in liver ischemia. Hepatogastroenterology. 1998;45:17811786.[Medline] [Order article via Infotrieve]
35. Nanjii AA, Khwaja S, Rahemtulle A, et al. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat. Gastroenterology. 1997;112:200207.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
G. Kewalramani, P. Puthanveetil, F. Wang, M. S. Kim, S. Deppe, A. Abrahani, D. S. Luciani, J. D. Johnson, and B. Rodrigues AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death Cardiovasc Res, October 1, 2009; 84(1): 42 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, Y. Li, L. Shan, E Shen, R. Chen, and T. Peng Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia Cardiovasc Res, July 1, 2009; 83(1): 72 - 79. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Peng, T. Zhang, X. Lu, and Q. Feng JNK1/c-fos inhibits cardiomyocyte TNF-{alpha} expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia Cardiovasc Res, March 1, 2009; 81(4): 733 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yuan, C. N. Perry, C. Huang, E. Iwai-Kanai, R. S. Carreira, C. C. Glembotski, and R. A. Gottlieb LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H470 - H479. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hocherl, C. Schmidt, B. Kurt, and M. Bucher Activation of the PGI2/IP System Contributes to the Development of Circulatory Failure in a Rat Model of Endotoxic Shock Hypertension, August 1, 2008; 52(2): 330 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF] |
||||
![]() |
T. Peng, E Shen, J. Fan, Y. Zhang, J. M. O. Arnold, and Q. Feng Disruption of phospholipase C{gamma}1 signalling attenuates cardiac tumor necrosis factor-{alpha} expression and improves myocardial function during endotoxemia Cardiovasc Res, April 1, 2008; 78(1): 90 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Scherz, J. Huisken, P. Sahai-Hernandez, and D. Y. R. Stainier High-speed imaging of developing heart valves reveals interplay of morphogenesis and function Development, March 15, 2008; 135(6): 1179 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Zhang, G.-R. Li, and J.-P. Bourreau The effect of adrenomedullin on the L-type calcium current in myocytes from septic shock rats: signaling pathway Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2888 - H2893. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Geoghegan-Morphet, D. Burger, X. Lu, V. Sathish, T. Peng, S. M. Sims, and Q. Feng Role of neuronal nitric oxide synthase in lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal mouse cardiomyocytes Cardiovasc Res, July 15, 2007; 75(2): 408 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G Raja and G. D Dreyfus Modulation of Systemic Inflammatory Response after Cardiac Surgery Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Mehra, V. S. Ramgolam, and J. R. Bender Cytokines and cardiovascular disease J. Leukoc. Biol., October 1, 2005; 78(4): 805 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Grandel, M. Hopf, M. Buerke, K. Hattar, M. Heep, L. Fink, R. M. Bohle, S. Morath, T. Hartung, S. Pullamsetti, et al. Mechanisms of Cardiac Depression Caused by Lipoteichoic Acids From Staphylococcus aureus in Isolated Rat Hearts Circulation, August 2, 2005; 112(5): 691 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Prabhu Cytokine-Induced Modulation of Cardiac Function Circ. Res., December 10, 2004; 95(12): 1140 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mittra, J.-M. Hyvelin, Q. Shan, F. Tang, and J.-P. Bourreau Role of cyclooxygenase in ventricular effects of adrenomedullin: is adrenomedullin a double-edged sword in sepsis? Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1034 - H1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Tessier, B. Thurner, E. Jungling, A. Luckhoff, and Y. Fischer Impairment of glucose metabolism in hearts from rats treated with endotoxin Cardiovasc Res, October 15, 2003; 60(1): 119 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. He, Y. Liu, V. Sharma, R. T. Dirksen, R. Waugh, S.-S. Sheu, and W. Min ASK1 Associates with Troponin T and Induces Troponin T Phosphorylation and Contractile Dysfunction in Cardiomyocytes Am. J. Pathol., July 1, 2003; 163(1): 243 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Degousee, J. Martindale, E. Stefanski, M. Cieslak, T. F. Lindsay, J. E. Fish, P. A. Marsden, D. J. Thuerauf, C. C. Glembotski, and B. B. Rubin MAP Kinase Kinase 6-p38 MAP Kinase Signaling Cascade Regulates Cyclooxygenase-2 Expression in Cardiac Myocytes In Vitro and In Vivo Circ. Res., April 18, 2003; 92(7): 757 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Peng, X. Lu, M. Lei, and Q. Feng Endothelial Nitric-oxide Synthase Enhances Lipopolysaccharide-stimulated Tumor Necrosis Factor-alpha Expression via cAMP-mediated p38 MAPK Pathway in Cardiomyocytes J. Biol. Chem., February 28, 2003; 278(10): 8099 - 8105. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Knuefermann, S. Nemoto, G. Baumgarten, A. Misra, N. Sivasubramanian, B. A. Carabello, and J. G. Vallejo Cardiac Inflammation and Innate Immunity in Septic Shock* : Is There a Role for Toll-Like Receptors? Chest, April 1, 2002; 121(4): 1329 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Grandel, M. Reutemann, L. Kiss, M. Buerke, L. Fink, E. Bournelis, M. Heep, W. Seeger, F. Grimminger, and U. Sibelius Staphylococcal alpha -toxin provokes neutrophil-dependent cardiac dysfunction: role of ICAM-1 and cys-leukotrienes Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1157 - H1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fink, S. Kohlhoff, M. M. Stein, J. Hanze, N. Weissmann, F. Rose, E. Akkayagil, D. Manz, F. Grimminger, W. Seeger, et al. cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue Am. J. Pathol., January 1, 2002; 160(1): 81 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mebazaa, G. W. De Keulenaer, X. Paqueron, L. J. Andries, P. Ratajczak, S. Lanone, C. Frelin, D. Longrois, D. Payen, D. L. Brutsaert, et al. Activation of Cardiac Endothelium as a Compensatory Component in Endotoxin-Induced Cardiomyopathy: Role of Endothelin, Prostaglandins, and Nitric Oxide Circulation, December 18, 2001; 104(25): 3137 - 3144. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |